Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.726
EU - Europa 11.939
AS - Asia 5.152
SA - Sud America 66
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 34
OC - Oceania 17
Totale 43.971
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.301
IT - Italia 2.625
DE - Germania 2.198
SG - Singapore 1.929
IE - Irlanda 1.758
CN - Cina 1.752
SE - Svezia 1.574
RU - Federazione Russa 1.203
UA - Ucraina 988
HK - Hong Kong 587
GB - Regno Unito 558
CA - Canada 419
FI - Finlandia 296
ID - Indonesia 226
VN - Vietnam 185
TR - Turchia 178
FR - Francia 175
IN - India 169
DK - Danimarca 117
BE - Belgio 97
NL - Olanda 69
PL - Polonia 56
AT - Austria 55
BG - Bulgaria 32
BR - Brasile 32
EU - Europa 32
JP - Giappone 32
IR - Iran 28
CZ - Repubblica Ceca 26
KR - Corea 22
RO - Romania 19
CH - Svizzera 17
AU - Australia 13
PT - Portogallo 13
ES - Italia 12
GR - Grecia 12
LT - Lituania 11
CL - Cile 10
MU - Mauritius 10
NO - Norvegia 10
MY - Malesia 8
PE - Perù 8
CO - Colombia 7
EG - Egitto 7
AR - Argentina 6
TN - Tunisia 6
PH - Filippine 5
RS - Serbia 5
SC - Seychelles 5
BD - Bangladesh 4
NZ - Nuova Zelanda 4
TH - Thailandia 4
AM - Armenia 3
EC - Ecuador 3
PK - Pakistan 3
TW - Taiwan 3
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EE - Estonia 2
HR - Croazia 2
JO - Giordania 2
KW - Kuwait 2
MK - Macedonia 2
MX - Messico 2
NG - Nigeria 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
HN - Honduras 1
IQ - Iraq 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MZ - Mozambico 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
UZ - Uzbekistan 1
YE - Yemen 1
Totale 43.971
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Woodbridge 2.706
Fairfield 2.295
Dublin 1.714
Houston 1.601
Singapore 1.531
Chandler 1.489
Frankfurt am Main 1.435
Wilmington 1.313
Ashburn 1.299
Milan 1.078
Jacksonville 1.040
Seattle 926
Dearborn 794
Cambridge 784
Santa Clara 687
New York 659
Hong Kong 576
Princeton 564
Nanjing 315
Shanghai 269
Altamura 249
Lawrence 249
Beijing 225
Jakarta 225
Göttingen 188
Lachine 173
San Diego 137
Boardman 127
Guangzhou 117
Lissone 101
Helsinki 100
Toronto 100
Andover 98
Nanchang 95
Brussels 93
Dong Ket 91
Shenyang 89
Ottawa 88
Fremont 80
Hebei 68
Fürstenwalde 65
Tianjin 64
Romola 62
Munich 61
Jiaxing 56
London 53
Lodz 52
Los Angeles 52
Jinan 49
Falls Church 48
Vienna 47
Norwalk 46
Kocaeli 45
Changsha 44
Rome 44
Kunming 42
Mountain View 42
Pune 41
Redmond 37
Edmonton 35
Hangzhou 32
Huizen 31
Washington 30
Chicago 28
Hefei 28
Cinisello Balsamo 27
Kiev 26
Zhengzhou 25
Monza 23
Moscow 21
Ningbo 21
Dallas 20
Plovdiv 20
Bonndorf 19
Carate Brianza 19
Turin 19
Bologna 18
Desio 18
Pavia 18
Como 17
Kilburn 16
Nürnberg 16
San Mateo 16
Bari 15
Detroit 15
St Petersburg 15
Leawood 14
Sacramento 14
Brno 13
Monmouth Junction 13
Taizhou 13
University Park 13
Daejeon 12
Fuzhou 12
Hounslow 12
Lappeenranta 12
Philadelphia 12
Buffalo 11
Delhi 11
Totale 33.642
Salva come PNG Salva come JPEG
Nome #
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 407
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 406
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 364
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 358
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 355
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 320
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 317
Acute myeloid leukaemia niche regulates response to L-asparaginase 316
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 310
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 309
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 308
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 305
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 304
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 291
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 289
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 288
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 280
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 275
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 274
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 273
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 272
Chronic myeloid leukemia: Second-line drugs of choice 270
Imatinib long term effects study: three years of follow-up and assessment 269
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 266
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 265
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 265
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 259
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 257
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 256
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 245
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 240
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 239
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 231
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 226
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 222
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 222
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 217
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 211
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 210
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 209
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 208
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 207
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 207
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 205
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 204
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 204
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 203
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 203
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 203
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 201
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 201
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 200
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 197
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 197
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 195
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 195
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 193
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 192
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 191
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 190
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 190
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 189
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 189
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 189
Inhibition of RET tyrosine kinase by SU5416 188
Reply to P. Laneuville et al 188
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 187
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 185
ALK inhibitors for clinical use in cancer therapy 185
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 184
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY 184
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 181
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 181
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 181
Expression, purification, and inhibition of human RET tyrosine kinase 180
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 179
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 178
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 177
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 175
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 174
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 173
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 172
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 171
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 171
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 170
Whole-Exome Sequencing Data - Identifying Somatic Mutations 170
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 169
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 167
ABL INHIBITOR BMS354825 BINDING MODE IN ABELSON KINASE REVEALED BY MOLECULAR DOCKING STUDIES 167
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 166
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 166
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis 166
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 166
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 165
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 165
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition 164
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 164
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 164
The ALK gene, an attractive target for inhibitor development 163
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 163
Totale 22.202
Salva come PNG Salva come JPEG
Categoria #
all - tutte 156.864
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 156.864
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.439 0 0 0 0 0 857 1.101 611 736 474 492 168
2020/20217.402 336 311 901 756 605 687 780 698 650 650 473 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/20255.278 790 1.498 734 665 1.115 476 0 0 0 0 0 0
Totale 45.728